StockNews.com started coverage on shares of IGC Pharma (NYSEAMERICAN:IGC – Free Report) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the construction company’s stock.
IGC Pharma Stock Up 19.8 %
IGC stock opened at $0.55 on Tuesday. The stock has a market capitalization of $37.07 million, a P/E ratio of -2.13 and a beta of 1.71. IGC Pharma has a 12 month low of $0.25 and a 12 month high of $0.91. The company has a current ratio of 1.85, a quick ratio of 0.86 and a debt-to-equity ratio of 0.02.
IGC Pharma (NYSEAMERICAN:IGC – Get Free Report) last posted its quarterly earnings results on Wednesday, February 14th. The construction company reported ($0.09) EPS for the quarter. The company had revenue of $0.20 million during the quarter. IGC Pharma had a negative return on equity of 110.37% and a negative net margin of 1,163.24%.
Institutional Inflows and Outflows
IGC Pharma Company Profile
IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.
Recommended Stories
- Five stocks we like better than IGC Pharma
- How to Invest in Small Cap StocksĀ
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Hilton Demonstrates Asset Light is Right for Investors
- There Are Different Types of Stock To Invest In
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.